Palisade Bio Presents Data Demonstrating PDE4B Expression In Patient Cohorts Could Be Utilized As A Potential Marker For Patient Stratification

Author: Benzinga Newsdesk | September 05, 2024 08:19am

Curated data show expression of PDE4B above a specific measurable threshold observed in 70% of adult colitis patients and 90% of pediatric colitis patients

Company is advancing lead program PALI-2108, an orally administered, locally acting colon-specific PDE4 inhibitor prodrug in development for patients affected by Ulcerative Colitis (UC)

Phase 1 human clinical study of PALI-2108 for the treatment of UC on track to commence before year end

 

Carlsbad, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio," or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the successful completion of refined patient selection strategies based on PDE4-related biomarkers and disease characteristics to optimize clinical outcomes for patients with UC as part of its collaboration with Strand Life Sciences ("Strand").

As part of the ongoing collaboration with Strand, RNAseq datasets were analyzed using a standardized bioinformatics pipeline, which generates normalized TPM counts for each gene. The analysis found that PDE4B expression is significantly higher in most colitis patients, encompassing both adult and pediatric cohorts. This suggests that PDE4B could be a crucial factor in patient stratification. In adults, a PDE4B over-expression level was determined that the Company believes accurately identifies 70% of moderate to severe cases. In pediatric patients, a PDE4B over-expression level was determined that the Company believes accurately identifies 90% of those with moderate to severe colitis.

Posted In: PALI